This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_BREAST_EXALLC for full statistics.
Carcinoma in situ of breast
CD2_INSITU_BREAST
breast ductal carcinoma in situ: A carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditions
|
269239 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpoints |
166 |
6. Filter based on genotype QC (FinnGen only) |
166 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 2
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D00-D09
- Name in latin
- Carcinoma in situ vulvae
Carcinoma in situ of breast
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 166 | 166 | - |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | - |
| Median age at first event (years) | 60.25 | 60.25 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 124
- Matched controls
- 1240
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D05.1
ICD-10 Finland
Intraductal carcinoma in situ
194.6
99.1
96
21
HA6AA
NOMESCO Finland
Extra corporeal mammography of operated mammary gland
13.3
19.0
34
34
PJA12
NOMESCO Finland
Sentinel node biopsy
7.4
16.7
44
86
D05.0
ICD-10 Finland
Lobular carcinoma in situ
97.7
16.0
17
*
HAB99
NOMESCO Finland
Other partial excision of mammary gland
11.6
14.4
27
29
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
8.6
13.8
31
46
D05.9
ICD-10 Finland
Carcinoma in situ of breast, unspecified
45.4
13.5
16
*
D48.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Breast
18.9
12.1
18
11
HAB50
NOMESCO Finland
Partial excision of mammary gland with reconstructive operation
12.2
10.7
19
18
HA4AT
NOMESCO Finland
Labeling mammary gland pathology with ultrasound guidance
9.9
10.6
21
25
WX402
NOMESCO Finland
General anaesthesia
4.3
10.4
44
140
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
18.7
10.2
15
9
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.5
9.6
60
261
HAB40
NOMESCO Finland
Wedge excision of mammary gland
5.3
9.0
28
64
WZC30
NOMESCO Finland
Teaching
4.6
8.4
30
80
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
10.5
8.0
15
16
XX3DW
NOMESCO Finland
Time consuming IT work
4.8
7.9
27
68
N63
ICD-10 Finland
Unspecified lump in breast
4.8
7.5
25
62
N64.5
ICD-10 Finland
Other signs and symptoms in breast
8.9
6.5
13
16
HAC20
NOMESCO Finland
Total mastectomy
6.0
6.4
17
32
D24
ICD-10 Finland
Benign neoplasm of breast
7.0
6.1
14
22
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
122
657
4.23
16.14
3.6
3.8
—
—
—
0
0
21
49
4.76
8.69
1.7
3.5
11.9
33.7
u/ml
0.90
21
49
57
323
2.16
4.97
1.9
2.1
—
—
—
0
0
104
779
1.90
3.81
5.4
5.6
9.0
9.7
umol/l
0.84
98
736
160
1464
3.57
3.20
14.2
13.7
139.9
139.9
mmol/l
0.02
160
1420
160
1468
3.49
3.04
14.4
13.7
3.9
3.9
mmol/l
0.21
160
1421
96
740
1.71
2.84
4.7
5.6
1.2
1.2
mmol/l
0.21
84
625
106
840
1.72
2.83
7.2
8.6
3.9
3.9
e9/l
0.13
89
729
19
87
2.34
2.69
2.0
1.5
—
—
—
0
0
7
20
3.61
2.08
1.3
1.4
—
—
—
0
0
22
121
1.94
2.00
2.3
1.8
—
—
—
0
0
7
21
3.43
1.99
1.3
1.4
—
—
—
0
0
7
21
3.43
1.99
1.3
1.4
—
—
—
0
0
7
22
3.27
1.90
1.6
1.4
—
—
—
0
0
7
22
3.27
1.90
1.6
1.4
—
—
—
0
0
7
22
3.27
1.90
1.6
1.3
—
—
—
0
0
21
116
1.93
1.89
2.0
1.6
—
—
—
0
0
76
600
1.49
1.75
4.7
3.7
37.0
35.9
g/l
0.99
70
558
8
32
2.57
1.62
1.1
1.2
—
—
—
0
0
155
1449
2.05
1.51
4.9
4.9
3.0
2.9
mmol/l
0.38
147
1338
10
45
2.30
1.49
1.0
1.2
—
—
—
0
0
9
39
2.38
1.45
1.2
1.3
—
—
—
0
0
147
1356
1.73
1.45
3.9
3.9
1.3
1.2
mmol/l
0.23
140
1245
6
22
2.79
1.45
1.0
1.5
—
—
—
0
0
11
53
2.15
1.42
1.0
1.3
—
4.2
—
0
13
42
305
1.50
1.41
1.1
1.3
12.8
34.1
iu/ml
—
8
113
148
1371
1.73
1.39
12.3
11.6
83.7
81.4
ml/min/173m2
0.77
126
1117
153
1431
1.88
1.38
4.4
4.4
5.0
4.9
mmol/l
0.37
147
1330
9
43
2.15
1.32
1.0
1.2
—
51.0
—
0
5
81
673
1.40
1.32
4.7
5.0
1.2
1.2
mmol/l
0.57
74
606
8
34
2.42
1.31
1.4
1.4
—
—
—
0
0
8
35
2.35
1.29
1.4
1.2
—
—
—
0
0
160
1533
2.21
1.23
11.5
10.0
24.6
23.9
u/l
0.21
160
1477
11
57
2.00
1.20
1.0
1.3
—
1.2
—
0
5
13
72
1.87
1.19
1.2
1.4
—
—
—
0
0
25
168
1.57
1.18
3.0
3.7
2.0
8.9
ug/l
1.80
17
139
42
316
1.44
1.18
1.4
1.6
0.7
1.0
mg/l
0.81
29
249
0
34
0.00
1.17
0.0
1.5
—
—
—
0
0
28
194
1.53
1.17
4.1
4.1
32.5
34.1
%
0.32
22
122
5
20
2.54
1.16
1.2
1.1
—
—
—
0
0
151
1422
1.68
1.11
4.4
4.4
1.6
1.6
mmol/l
0.01
144
1314
19
123
1.62
1.05
1.7
3.6
—
—
—
0
0
5
23
2.21
0.98
1.4
1.2
—
—
nmol/l
—
0
0
0
31
0.00
0.97
0.0
1.1
—
2.0
—
0
18
29
381
0.71
0.89
4.8
3.7
0.0
0.0
estimate
—
9
137
0
24
0.00
0.80
0.0
1.8
—
—
—
0
0
61
520
1.27
0.75
2.1
3.4
2.4
2.4
mmol/l
0.87
52
458
7
38
1.88
0.74
1.7
3.4
24.6
25.4
mmol/l
—
7
38
5
27
1.88
0.69
1.4
1.4
—
—
—
0
0
141
1339
1.35
0.67
5.6
5.2
39.2
39.1
mmol/mol
0.04
132
1244
5
30
1.69
0.62
1.2
1.6
—
—
—
0
0
0
20
0.00
0.61
0.0
1.0
—
—
—
0
0
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
0
22
0.00
0.60
0.0
1.0
—
—
—
0
0
37
443
0.79
0.59
1.8
1.7
1.4
1.3
mmol/l
0.25
37
377
26
324
0.77
0.57
1.5
1.4
23.4
22.6
nmol/l
0.06
20
267
23
180
1.32
0.53
1.3
1.6
29.0
29.5
s
0.22
23
175
9
64
1.43
0.52
1.4
1.3
—
—
—
0
0
44
376
1.23
0.52
1.6
1.4
—
—
—
0
0
146
1407
1.31
0.49
4.7
4.4
5.9
5.8
mmol/l
0.60
136
1303
7
47
1.51
0.48
2.4
2.0
—
—
—
0
0
31
257
1.25
0.48
3.3
3.4
71.5
404.7
ng/l
0.72
24
185
10
69
1.48
0.45
1.3
1.9
—
—
—
0
0
118
1117
1.20
0.44
4.9
4.0
11.3
11.7
mm/h
0.13
112
1028
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
28
331
0.81
0.40
1.9
2.4
308.0
6405.4
umol/l
1.81
21
286
0
18
0.00
0.40
0.0
1.2
—
6.9
—
0
12
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
36
312
1.20
0.37
1.3
1.3
6.1
8.7
u/ml
0.20
14
128
161
1581
1.61
0.36
20.8
18.4
133.8
132.4
g/l
0.91
161
1555
6
42
1.44
0.36
1.8
1.5
375.8
285.8
mu/l
—
6
37
6
87
0.68
0.34
1.2
1.4
—
—
—
0
0
31
269
1.19
0.32
1.8
1.4
—
—
—
0
0
15
120
1.27
0.31
1.9
1.8
—
—
—
0
0
140
1435
0.84
0.28
13.3
12.1
15.5
20.1
mg/l
1.75
119
1087
10
127
0.77
0.26
2.0
4.7
214.7
254.0
u/l
—
10
120
15
123
1.24
0.26
1.9
1.8
—
—
—
0
0
25
218
1.17
0.25
1.9
2.6
1.1
1.0
e6/l
0.06
14
117
59
550
1.11
0.23
2.2
1.9
100.7
100.2
pmol/l
0.03
30
255
5
40
1.26
0.22
1.8
1.5
0.0
0.0
g/l
—
5
40
5
40
1.26
0.22
1.8
1.6
0.0
0.1
g/l
—
5
40
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
4.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
3.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
38
347
1.12
0.21
2.1
2.7
303.7
1015.0
ng/l
3.55
32
288
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
1.3
—
0
7
88
917
0.91
0.19
3.2
3.0
—
—
—
0
0
6
52
1.16
0.19
2.3
1.3
—
—
—
0
0
5
69
0.72
0.17
3.6
2.8
13.4
1915.6
u/ml
—
5
62
8
68
1.19
0.17
1.6
2.9
5.1
5.2
kpa
—
8
61
30
276
1.11
0.15
2.5
2.6
2.5
2.5
mmol/l
0.04
24
240
10
84
1.20
0.14
1.1
1.0
—
—
—
0
0
11
128
0.85
0.14
3.2
2.1
0.2
0.2
g/l
0.56
11
119
33
308
1.09
0.12
2.4
2.0
2.2
3.1
mg/l
2.27
27
265
132
1298
1.08
0.12
15.0
13.2
37.9
39.3
%
0.78
100
967
20
182
1.11
0.11
1.8
1.9
—
—
—
0
0
35
372
0.93
0.11
1.5
1.2
0.5
2.6
u/ml
—
9
110
123
1207
1.07
0.11
6.0
4.3
14.7
14.6
pmol/l
0.10
115
1114
74
716
1.06
0.11
3.5
3.6
0.0
0.0
estimate
—
9
129
69
667
1.06
0.10
2.6
2.2
80.8
79.3
nmol/l
0.17
61
595
73
707
1.06
0.10
3.5
3.6
0.0
0.0
estimate
—
8
133
10
87
1.16
0.09
1.1
2.7
51.6
126.7
ng/l
—
10
79
5
47
1.07
0.09
1.4
2.0
—
—
—
0
0
5
47
1.07
0.09
1.4
1.8
—
—
—
0
0
5
48
1.04
0.09
1.4
1.2
—
—
—
0
0
22
204
1.09
0.09
1.9
2.8
2.1
4.3
e6/l
0.89
11
103
7
67
1.05
0.08
1.1
2.1
31.4
41.1
u/l
—
7
59
7
67
1.05
0.08
1.3
1.7
—
—
—
0
0
17
183
0.92
0.07
6.0
4.6
—
—
—
0
0
48
496
0.95
0.06
2.7
3.2
10.5
31.2
ng/l
1.73
29
315
53
544
0.96
0.05
3.5
3.7
—
—
—
0
0
11
103
1.07
0.02
4.1
5.3
1.1
1.2
mmol/l
0.17
11
98
38
372
1.03
0.02
2.4
3.0
0.1
0.5
e6/l
1.62
28
271
24
233
1.04
0.01
2.3
1.6
980.4
1169.5
nmol/l
0.52
17
171
12
126
0.95
0.00
1.3
1.2
152.0
173.3
iu/ml
—
6
57
15
153
0.98
0.00
1.5
1.7
—
—
—
0
0
47
468
1.01
0.00
2.6
3.0
—
—
—
0
0
71
711
1.00
0.00
5.0
5.0
0.0
0.0
estimate
—
8
133
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
2286.6
—
0
5
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
5
55
0.91
0.00
1.8
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
55
0.91
0.00
1.8
1.4
3.5
3.8
g/l
—
5
43
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
5
55
0.91
0.00
1.8
1.4
6.9
7.8
g/l
—
5
46
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
51
0.98
0.00
1.0
3.2
28.4
24.4
mmol/l
—
5
46
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
122
1220
1.00
0.00
17.8
15.2
13.5
13.7
%
0.79
122
1201
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
0.00
1.8
1.4
2.4
3.2
g/l
—
5
43
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
6
63
0.95
0.00
2.5
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
0.00
1.4
3.3
33.7
46.6
%
—
5
49
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_BREAST – Carcinoma in situ of breast
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).